Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $19,638.50 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 2,534 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total transaction of $19,638.50. Following the sale, the insider now owns 269,794 shares of the company’s stock, valued at approximately $2,090,903.50. This trade represents a 0.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $7.65 on Thursday. Aura Biosciences, Inc. has a 12 month low of $6.63 and a 12 month high of $12.38. The stock has a market capitalization of $382.12 million, a price-to-earnings ratio of -4.42 and a beta of 0.29. The firm has a fifty day simple moving average of $8.02 and a two-hundred day simple moving average of $8.74.

Hedge Funds Weigh In On Aura Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in AURA. BNP Paribas Financial Markets bought a new stake in Aura Biosciences in the 4th quarter valued at about $50,000. China Universal Asset Management Co. Ltd. acquired a new stake in Aura Biosciences in the fourth quarter valued at approximately $87,000. ProShare Advisors LLC bought a new stake in shares of Aura Biosciences during the fourth quarter valued at approximately $127,000. Harvest Investment Services LLC acquired a new position in shares of Aura Biosciences during the fourth quarter worth approximately $133,000. Finally, AlphaQuest LLC bought a new position in shares of Aura Biosciences in the 4th quarter worth $136,000. Institutional investors own 96.75% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on AURA shares. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.